Optimi Health Corp. (OPTH)
| Market Cap | 19.34M -25.1% |
| Revenue (ttm) | 123,703 -68.0% |
| Net Income | -4.86M |
| EPS | -1.41 |
| Shares Out | 5.73M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18,729 |
| Open | 3.490 |
| Previous Close | 3.360 |
| Day's Range | 3.269 - 3.580 |
| 52-Week Range | 3.040 - 8.838 |
| Beta | 1.58 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Dec 8, 2026 |
About OPTH
Optimi Health Corp. operates as a pharmaceutical and nutraceutical drug manufacturing company in Canada. The company manufactures controlled substances including finished MDMA and psilocybin drug products, supplying them directly to authorized clinics, pharmacies, clinical trials, and partners. The company produces and supplies MDMA, natural psilocybin, psilocin, other psychedelic substances, and functional mushrooms derived from botanical sources for health and wellness markets. The company also engages in farming, processing, and distribution... [Read more]
Financial Performance
In fiscal year 2025, Optimi Health's revenue was 426,301, an increase of 9.35% compared to the previous year's 389,850. Losses were -3.71 million, -38.50% less than in 2024.
Financial numbers in CAD Financial StatementsNews
Optimi Health Completes MDMA Production For Phase 3 PTSD Trial And International Supply
(RTTNews) - Optimi Health Corp. (OPTH) announced the completion of a new production batch of its MDMA capsules intended to support a proposed Phase 3 clinical trial for post-traumatic stress disorder ...
Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia
Batch sufficient to supply the proposed Canadian Phase 3 trial, a clinical trial in Israel in partnership with MAPS and a commercial export to treat PTSD in Australia Health Canada-authorized trial to...
Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia
Batch sufficient to supply the proposed Canadian Phase 3 trial, a clinical trial in Israel in partnership with MAPS and a commercial export to treat PTSD in Australia Health Canada-authorized trial to...
Optimi Health Transcript: The ThinkEquity Conference
Australian distribution is active, with clinic expansion targeted over the next year. Phase II psilocybin and phase III MDMA programs, research-focused Ibogaine supply by year-end, and policy shifts form key catalysts.
Optimi Health to Present at the ThinkEquity Conference
VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) — Optimi Health Corp. (Nasdaq: OPTH) (CSE: OPTI) (FSE: 8BN) (“Optimi” or “the Company”), a commercial-stage pharmaceutical manufacturer and ...
Optimi Health to Present at the ThinkEquity Conference
VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: OPTH) (CSE: OPTI) (FSE: 8BN) (“Optimi” or “the Company”), a commercial-stage pharmaceutical manufacturer and...
Optimi Health Appoints Melanie Pump to Board of Directors
Seasoned finance executive brings more than 25 years of leadership experience across technology, digital infrastructure, software, fintech and emerging growth companies Seasoned finance executive brin...
Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply
VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of...
Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer
Supports Optimi’s planned Phase 2 psilocybin trial in major depressive disorder and Phase 3 MDMA trial in PTSD VANCOUVER, British Columbia, Sept. 22, 2026 (GLOBE NEWSWIRE) — Optimi Health Corp. (NASDA...
Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer
VANCOUVER, British Columbia, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of...
Optimi Health Plans Phase 3 Trial Of MDMA-Assisted Therapy For PTSD
(RTTNews) - Optimi Health Corp. (OPTH) announced plans to initiate a Health Canada-authorized Phase 3 clinical trial evaluating its synthetic MDMA-assisted therapy for post-traumatic stress disorder (...
Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder
Health Canada-authorized trial to evaluate efficacy and safety of two sessions of MDMA-assisted therapy in up to 100 veterans and frontline workers VANCOUVER, British Columbia, Sept. 16, 2026 (GLOBE N...
Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder
Health Canada-authorized trial to evaluate efficacy and safety of two sessions of MDMA-assisted therapy in up to 100 veterans and frontline workers Health Canada-authorized trial to evaluate efficacy ...
Optimi Health Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Currently commercial with psilocybin and MDMA products in Australia and Canada, the company is expanding globally as regulatory frameworks evolve. Insurance reimbursement and rapid clinic adoption in Australia highlight strong market traction, while U.S. and Canadian policy shifts signal further growth opportunities.
Optimi Health to initiate Phase 2 trial of psilocybin-assisted therapy for MDD
Optimi Health (OPTH) announces plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for individuals with major depressive disorder. The trial is planned to be in...
Optimi Health To Initiate Phase 2 Psilocybin Trial For Major Depression
(RTTNews) - Optimi Health Corp. (OPTH), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, announced plans to initiate a multisite Phase 2 clinical trial evaluating...
Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
Health Canada-authorized trial to evaluate a single supervised dose of natural psilocybin, with dosing expected to be completed by the end of 2027 Up to 200 participants at sites across Canada, among ...
Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
Health Canada-authorized trial to evaluate a single supervised dose of natural psilocybin, with dosing expected to be completed by the end of 2027
Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) — Optimi Health Corp. (Nasdaq: OPTH) (CSE: OPTI) (“Optimi” or the “Company”), a commercial-stage pharmaceutical manufacturer of regulated p...
Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: OPTH) (CSE: OPTI) (“Optimi” or the “Company”), a commercial-stage pharmaceutical manufacturer of regulated ...
Optimi Health Registration statement: Registration filing
Optimi Health filed a registration statement on August 17, 2026, providing details about a securities offering with the SEC.
Optimi Health files to sell 21.94M common shares for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 21.94M common shares. The company is not selling any shares under…
Optimi Health files to sell 21.94M common shares for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 21.94M common shares. The company is not selling any shares under…
Optimi Health establishes discretionary equity facility
Optimi Health (OPTH) announced that it has entered into a common shares purchase agreement with Seven Knots, establishing an equity line of credit under which the company has the right,…
Optimi Health Report: Q3 2026
Optimi Health published a report on August 14, 2026 containing material business information for investors and shareholders.